IP Library Granted Patent US 8,026,263
Granted Patent B2
US 8,026,263 · App. 10/533,060 · Granted Sep 27, 2011

Methods for inhibiting neoproliferative changes in blood vessel walls

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,026,263
App. No.
10/533,060
Granted
Sep 27, 2011
Kind
B2
Abstract

Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are administered systemically and/or locally to human or veterinary patients to deter or prevent unwanted proliferative changes in blood vessels or other anatomical structures. The invention may be used to deter or prevent stenosis or restenosis of arteries following angioplasty and/or stent placement. In one embodiment, there is provided an implantable stent or stent graft from which one or more compounds of the present invention will elute or otherwise be delivered into an affected blood vessel wall.

Claims (34)

1. A method for deterring, inhibiting or reversing stenosis, restenosis or unwanted proliferation of an artery in a human or veterinary patient, said method comprising the step of:

administering to the patient a compound having the structural formula

Wherein,

X, Y and Z are same or different and are independently selected from CH2, O, S, NR 1 , N═CH, CH═N and R 2 —C═C—R 3 , where R 2 and R 3 are H or may combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R groups;

R 1 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl, optionally substituted with hydroxy, amino, substituted amino, cyano, alkoxy, halogen, trihaloalkyl, nitro, thio, alkylthio, carboxy and alkoxycarbonyl groups;

R is selected from H, halogen, trihaloalkyl, hydroxy, acyloxy, alkoxy, alkenyloxy, thio, alkylthio, nitro, cyano, ureido, acyl, carboxy, alkoxycarbonyl, N—(R 4 )(R 5 ) and saturated or unsaturated, chiral or achiral, cyclic or acyclic, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms, optionally substituted with hydroxy, halogen, trihaloalkyl, alkylthio, alkoxy, carboxy, alkoxycarbonyl, oxoalkyl, cyano and N—(R 4 )(R 5 ) group,

R 4 and R 5 are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl and acyl or R 4 and R 5 may combine to form a ring, wherein a carbon may be optionally substituted by a heteroatom selected from O, S or N—R 6 ,

R 6 is H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl or carboxyalkyl,

n is 1-5; m is 1 or 2; with the proviso that

when m is 1, Q is selected from OH, CN, carboxyalkyl, N—(R 7 )(R 8 ), where R 7 and R 8 are selected from H, lower alkyl (1-4C), cycloalkyl, aryl, acyl, amido, or R 7 and R 8 may combine to form a saturated or unsaturated heterocylic ring and optionally substituted with up to 3 additional heteroatoms selected from N, O, and S; or

—NH-heterocycle, where the heterocycle is represented by thiazole, oxazole, isoxazole, pyridine, pyrimidine, and purine and

where U and V are selected from H and O; and

when m is 2, Q is a spacer of from 2-10 carbons as a straight or branched, chiral or achiral, cyclic or acyclic, saturated or unsaturated, hydrocarbon group, such as phenyl;

In the most preferred embodiment of this invention,

X, Y, and Z are R 2 —C═C—R 3 , where R 2 and R 3 are H;

R is selected from H and halogen, preferably, F and Cl;

m is 1; and

Q is —N—(R 7 )(R 8 ), where R 7 and R 8 are selected from H, acyl, amido, and R 7 and R 8 combine to form a saturated or unsaturated heterocyclic ring, optionally substituted with up to three heteroatoms selected from N, O, or S, for example, pyrrolidine, piperidine, pyrazole, imidazole, oxazole, isoxazole, tetrazole, azepine, etc., which may be optionally substituted with a lower alkyl or amino group;

wherein the compound is administered at a dose that effectively deters, inhibits or reverses stenosis, restenosis or unwanted proliferation of an artery but does not inhibit hepatic cytochrome P450 enzyme activity.

2. A method according to claim 1 wherein the X, Y, and Z are each R 2 —C═C—R 3 ; R 2 and R 3 are H; R is selected from H and halogen m is 2; and Q is a spacer of from 2-10 carbons either as a straight or branched hydrocarbon chain or as a containing a hydrocarbon ring.

3. A method according to claim 1 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole.

4. A method according to claim 1 wherein the compound is 1-[(2-fluorphenyl)diphenylmethyl]-1H-pyrazole.

5. A method according to claim 1 wherein the compound is 1-[(4-chlorophenyl)diphenylmethyl]-1H-pyrazole.

6. A method according to claim 1 wherein the compound is 1-[(2-fluorphenyl)diphenylmethyl]-1H-pyrazole.

7. A method according to claim 1 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1H-1,2,3,4-tetrazole.

8. A method according to claim 1 wherein the compound is administered to the patient orally.

9. A method according to claim 1 wherein the compound is administered to the patient by injection.

10. A method according to claim 1 wherein the compound is administered to the patient transdermally.

11. A method according to claim 1 wherein the compound is administered to the patient transmucosally.

12. A method according to claim 1 wherein the compound is on or in an implantable device and wherein the compound is administered to the patient by implanting the device within the patient's body such that the compound elutes from the implanted device.

13. A method according to claim 12 wherein the device comprises a stent.

14. A method according to claim 13 wherein the stent is implanted in an artery of the patient such that a therapeutically effective amount of the compound elutes from the stent and deters reocclusion of the artery in which the stent is implanted.

15. A method according to claim 13 wherein the stent is implanted in a coronary artery of the patient such that a therapeutically effective amount of the compound elutes from the stent and deters reocclusion of the coronary artery in which the stent is implanted.

16. A method according to claim 1 wherein the compound is administered to a patient who has undergone or will undergo an angioplasty, atherectomy and/or stent implantation to treat an occluded blood vessel and wherein the compound is administered in an amount and by a route of administration that is effective to deter reocclusion of the blood vessel.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 25, 2011
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026642/0263 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Oct 27, 2008
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021743/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2006
From: WULFF, HEIKE; KOEHLER, RALF; HOYER, JOACHIM; CHANDY, K. GEORGE
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Reel/Frame 017372/0588 →
Continuity (3)
Continuation In Part 09479391 · Jan 6, 2000
Provisional Application 60422712 · Oct 30, 2002
Related Publication 20090048270A1 · Feb 19, 2009